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Abstract: A recently published ERS core outcome set recommends that all trials of COPD 
exacerbation management should assess the treatment success (or “cure” of the exacerbation), 
defined as a dichotomous measure of the overall outcome of an exacerbation. This methodological 
systematic review describes and compares the instruments that were used to assess treatment 
success or failure in 54 such RCTs, published between 2006–2020. Twenty-three RCTs used 
composite measures consisting of several undesirable outcomes of an exacerbation, together 
defining an overall unfavourable outcome, to define treatment failure. Thirty-four RCTs used 
descriptive instruments that used qualitative or semi-quantitative descriptions to define cure, 
marked improvement, improvement of the exacerbation, or treatment failure. Treatment success 
and failure rates among patients receiving guidelines-directed treatments at different settings and 
timepoints are described and could be used to inform power calculations in future trials. Descriptive 
instruments appeared more sensitive to treatment effects compared to composite instruments. 
Further methodological studies are needed to optimise the evaluation of treatment success/failure. 
In the meantime, based on the findings of this systematic review, the ERS core outcome set 
recommends that cure should be defined as sufficient improvement of the signs and symptoms of 
the exacerbation such that no additional systemic treatments are required. 
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While our understanding of the mechanisms of acute exacerbations of chronic 
obstructive pulmonary disease (COPD) is expanding, their management has remained 
suboptimal and unchanged for many years [1,2]. Therefore, there is an urgent need to 
develop effective treatments and test them in high-quality randomised controlled trials 
(RCTs). The significant complexity and heterogeneity of COPD exacerbations has proven 
to be a substantial hindrance to the discovery of novel treatments. Nevertheless, the 
differential aetiology of exacerbations (e.g., events caused by bacterial or viral infections, 
or triggered by enhanced eosinophilic inflammation), is progressively being disentangled 
revealing targets for precision medicine interventions [3–6]. The clinical validation of 
biomarkers, such as procalcitonin or blood eosinophils, and aetiological classification of 
exacerbations may facilitate the future introduction of targeted treatments in clinical 
practice [3–6]. Precision medicine interventions for COPD exacerbations management are 
anticipated to be tested in rigorous RCTs in the coming years. The DECODE-NET 
(DisEntangling Chronic Obstructive Pulmonary Disease Exacerbations—an international 
clinical trials network) involving over 50 centres with expertise in COPD exacerbations 
trials research globally, is committed to conducting such RCTs [7]. 
RCTs on the management of COPD exacerbations are complicated both regarding 
design and conduct [7]. Different methodological aspects of such RCTs were evaluated in 
a recent systematic review, that revealed significant heterogeneity in the definition and 
diagnostic criteria of COPD exacerbations, as well as the outcomes (endpoints) evaluated 
across trials of COPD exacerbations management [8,9]. It is crucial that trials evaluating 
the management of a disease entity assess the same outcomes, those important to patients 
and health professionals, to facilitate decision making and improve the comparability of 
the trial results [10]. For this reason, the European Respiratory Society (ERS) launched a 
task force that developed a core outcome set for RCTs on the management of COPD 
exacerbations [11,12]. A core outcome set is an agreed standardised set of critically 
important outcomes that should be measured and reported as a minimum in all clinical 
trials in specific areas of health and health care [10]. 
The assessment of the overall outcome of the exacerbation (treatment success/failure, 
or cure) was selected as a core outcome, to be assessed in all future RCTs [12]. Moreover, 
a recent methodological systematic review revealed that this outcome is the second most 
frequently evaluated outcome in therapeutic trials of COPD exacerbations [9]. However, 
the definitions and instrument used to evaluate this outcome are very heterogeneous, 
limiting the interpretability and comparability of trial results. This meta-epidemiological 
study was conducted to inform the core outcome set and aimed to systematically evaluate 
the measurement instruments used for assessing treatment success or failure, to explore 
how effective they are, and which timepoints are more sensitive. 
2. Materials and Methods 
This meta-epidemiological study was based on a prospectively registered protocol 
(PROSPERO ID: CRD42020222287) [13]. For conducting and reporting this systematic 
review, we followed the standard methodology recommended by the Cochrane 
Collaboration [14] and the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) statement [15], respectively. 
We systematically searched Medline/PubMed, the Cochrane Airways Trials Register 
[16], and the COSMIN (Consensus-based Standards for the Selection of Health 
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Measurement Instruments) database on 12 November 2020, to identify trials testing 
pharmacological and non-pharmacological interventions for the management of COPD 
exacerbations. We also looked for methodological studies assessing the performance 
characteristics of different instruments for assessing treatment success or failure in clinical 
trials on COPD exacerbations. Detailed search strategies are available in Appendix A. 
Ongoing and completed trials and relevant methodological studies reported in the 
English language during the last 15 years (from 2006 onwards) were considered eligible. 
The titles and abstracts of all studies identified through the searches and the full texts of 
all potentially eligible studies were independently evaluated for eligibility by two review 
authors. We selected studies reporting on any of the following outcomes: cure, resolution, 
treatment success, treatment failure, time-to-cure, time-to-resolution, time-to-treatment 
success, or time-to-treatment failure. Relevant data on the design, interventions, baseline 
characteristics and imbalances, as well as data on the outcomes of interest, including the 
definitions used, measurement timepoints, and outcome data (findings) were extracted in 
a structured Excel form by one author and cross-checked by a second review author. The 
risk of methodological bias was assessed using the Cochrane Risk of Bias 1 tool by one 
author and cross-checked by a second author [17]. Disagreement in each stage of the 
process was resolved by consensus, involving a third author. 
For the purposes of this review, we defined treatment success/failure, or cure of the 
exacerbation, as a dichotomous measure of the overall outcome of the exacerbation (Table 
1). We excluded continuous measures evaluating changes in variables without 
prespecified thresholds of success or failure (e.g., change in symptom scores from 
baseline) and outcomes that did not focus on an overall assessment of the treatment 
outcome but on specific aspects of the exacerbation (e.g., death; admission to the intensive 
care unit; hospital admission; bacteriological eradication). 




e, or cure 
A dichotomous measure of the overall outcome of the exacerbation. We  
excluded continuous measures evaluating a change in variables without  
prespecified thresholds of success or failure (e.g., change in symptom 
scores from baseline) and outcomes that did not focus on an overall  
assessment of the treatment outcome but on specific aspects of the  
exacerbation (e.g., death; hospital admission; bacteriological eradication). 
Composite 
instruments 
Instruments consisting of several undesirable outcomes of an exacerbation 
(e.g., death; need for treatment intensification; admission to the intensive 




Instruments defining treatment success or failure based on qualitative or 
semi-quantitative descriptions of the patients’ clinical status with regards 
to the exacerbation at a specific timepoint. The following states are often 
defined: cure, marked improvement, improvement, or treatment failure. 
The definitions and timepoints of evaluation of the relevant outcomes were described 
narratively and in a tabulated format. Instruments used to measure the outcome of 
interest were grouped based on their characteristics into (i) composite instruments and (ii) 
descriptive instruments (definitions in Table 1). Grouping was based on consensus among 
the authors. 
Treatment success or failure is a time-dependent outcome. Therefore, it is crucial to 
select the optimal timepoint for evaluating this outcome. For this reason, we explored the 
proportion of participants receiving usual care that fulfilled the criteria of treatment 
success or failure at different timepoints. Studies were stratified according to (i) the 
instrument used for assessing treatment success and (ii) the treatment setting that was 
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considered to reflect the severity of the exacerbations. In this analysis, we included all 
treatment arms of the included trials in which participants received treatments that are 
consistent with international guideline recommendations (i.e., we excluded study arms 
that received novel experimental treatments). 
Finally, to assess which instrument group and timepoints are more effective in 
identifying treatment effects, we explored between-group differences in treatment success 
or failure in trials assessing an intervention hypothesised by the trial investigators to be 
superior to the control group treatment (i.e., trials evaluating additional treatment 
compared to standard care; we excluded non-inferiority trials or trials comparing 
treatments without a prospective hypothesis around superiority). Outcome data from 
studies that were eligible for this analysis are presented in forest plots and described 
narratively. 
3. Results 
After removing duplicate records and conference abstracts, our searches yielded 3349 
records. The selection process is described in a PRISMA diagram (Figure A1). We did not 
identify any eligible methodological studies evaluating the performance characteristics of 
instruments used to assess treatment success or failure in COPD exacerbations trials. We 
identified 176 ongoing or completed RCTs evaluating pharmacological or non-
pharmacological interventions for the management of COPD exacerbations, of which 54 
(30.7%) assessed the overall outcome of the index exacerbation (treatment success or 
treatment failure; references of all included studies are available in the online Appendix 
A). This was selected as the primary outcome in 35 (64.8%), and as a secondary outcome 
in 19 (35.2%) of these trials. Timepoints of evaluation of this outcome varied from 2 h to 1 
year after recruitment across the included trials. The interventions evaluated in the 54 
included RCTs were antibiotics (n = 28), anti-inflammatories (11), oxygenation or non-
invasive ventilation techniques (8), Chinese traditional medicine (3), or other 
interventions (4). 
Two categories of outcome measurement instruments for evaluating treatment 
success or failure were revealed: composite and descriptive instruments (definitions in 
Table 1). 
3.1. Composite Endpoints Consisting of Several Undesirable Outcomes of an Exacerbation 
Twenty-three RCTs included 27 composite measurement instruments [4,18–39]. Most 
of these RCTs were at high or unclear risk of methodological bias. High risk of 
performance or detection bias was observed in 12/23 (52.2%) and 11/23 (47.8%) RCTs, 
respectively. Only six RCTs were deemed to be of an overall low risk of bias (Table 2). 






































Aaron 2013 Low Low Low Low Low Low Low 
Aggarwal 2011 Low Unclear High High Low Unclear Unclear 
Bafadhel 2012 Low Low Low Low Low Low Low 
Carrera 2009 Low Low Low Low High Unclear Low 
Corrado 2009 Low Low High High Low Unclear Unclear 
Daniels 2010 Low Low Low Low Low High Low 
de Jong 2007 Low Unclear Low Low Low Low Low 
Goossens 2013 Low Low High High Low Low Low 
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Hua 2020 Low Low High High     
Jolliet 2016 Low Unclear High Low Low Low Low 
Nicolini 2014 Low Low High High Low Low Low 
Nouira 2010 Low Low Low Low Low Low Low 
Papalampidou 2020 Low High High High     
Prasad 2020 Low Low High High Low Low High 
Sehgal 2019 Low Low High High Low Low Low 
Sivapalan 2019 Low Low High High Low Low Low 
Strambu 2019 Low Low Low Low Low Low Low 
Tajamul 2020 Low Low High High Low Low Low 
Urueta-Robledo 2006 Unclear Unclear Low Low High Unclear Unclear 
van Velzen 2017 Low Low Low Low Low Low Low 
van Zanten 2007 Unclear Unclear High High Low Unclear Low 
Vermeersch 2019 Low Low Low Low Low Low Low 
Wilson 2015  Unclear Unclear Low Low High Low Low 
Woodruff 2011 Unclear Unclear Low Low High Low High 
Each composite instrument included a median of three (range 2–5) components. 
These components described different undesirable events and if any of these events was 
fulfilled then participants were considered to have experienced treatment failure. The 
most frequently used components were death (n = 16, 59.3% of the outcomes), need for 
hospital admission or re-admission (14, 51.9%), and treatment intensification (14, 51.9%). 
More details are summarised in Table 3. 
Table 3. Undesirable outcomes included in the composite treatment failure instruments, along with 
the frequency in which they were utilised. 
Components of the Composite Outcome Definitions N (%) 
Death 16 (59.3%) 
Need for hospital admission/re-admission 14 (51.9%) 
Need for treatment intensification 14 (51.9%) 
Need for endotracheal intubation/mechanical ventilation 10 (37.0%) 
Persistent or deteriorating symptoms and signs 8 (29.6%) 
Need for non-invasive ventilation 3 (11.1%) 
Need for urgent outpatient or emergency room visit 3 (11.1%) 
New infection 3 (11.1%) 
Need for higher level of hospital care 2 (7.4%) 
Deteriorated arterial blood gases 1 (3.7%) 
Hemodynamic instability 1 (3.7%) 
Need for ICU admission 1 (3.7%) 
Prolonged hospital stay 1 (3.7%) 
Reduced level of consciousness 1 (3.7%) 
Treatment intolerance 1 (3.7%) 
3.2. Qualitative or Semi-Quantitative Descriptions of the Participants’ Clinical Status 
Thirty-four RCTs included 45 descriptive instruments [37–70]. All but three trials 
were deemed to be at high risk of methodological bias. A high risk of performance or 
detection bias was revealed in 16 (47.1%) and 13 (38.2%) of the 34 studies, respectively 
(Table 4). Four states were defined: cure, marked improvement, improvement, and 
treatment failure. The definitions of these states differed across the included trials (Table 
5). Moreover, the definition of clinical effectiveness varied. While in most trials, cure of 
the exacerbation or the absence of treatment failure was defined as treatment success, 
other trials accepted marked improvement, or, less frequently, improvement as an 
Biomedicines 2021, 9, 1837 6 of 21 
 
indicator of effectiveness (Table 5). The previous terms were used in many of the included 
trials. The instruments described in the remaining trials were matched to the most 
appropriate states by consensus among the investigators. 
3.3. Proportion of Participants Experiencing Treatment Success or Failure over Time 
Treatment success or failure is a time-sensitive outcome. Too early or too late during 
the exacerbation, nearly none or all the participants will have fulfilled the criteria of 
success or failure, respectively, limiting the ability of the outcome to detect between-group 
differences in clinical trials. For this reason, we explored the proportion of participants 
fulfilling the outcomes of interest at different timepoints. 
Figure 1 depicts the proportion of study participants in treatment arms treated with 
guideline-recommended treatments (usual care) that experienced treatment failure as 
judged by composite outcome measurement endpoints (defined based on several 
undesirable outcomes of an exacerbation). This outcome was assessed at different 
timepoints, mostly within a month from recruitment, although in some trials it was tested 
at up to three months follow-up (and in one case at 9 months; not included in Figure 1). 
 
Figure 1. Treatment failure rates assessed using composite measurement instruments among 
participants in arms of the included trials that received treatments/interventions that are consistent 
with current clinical practice guidelines (i.e., study arms with experimental interventions that are 
not consistent with current clinical practice were excluded from this analysis). 






































Alvarez-Sala 2006 Unclear Unclear Low Low Low Unclear Unclear 
Andre-Alves 2007 Unclear Unclear High High Low Unclear High 
Blasi 2013 Unclear Unclear High High Low Low Unclear 
Blasi 2013 B Low Low Low Low Low Unclear High 
Brusse-Keizer 2014 Low Low Low Low Low Low High 
Ceviker 2014 Low Low High Low High Unclear Unclear 
Chatterjee 2011 Low Low High Low Low Unclear Unclear 
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Daniels 2010 Low Low Low Low Low High Low 
Gao 2019 Unclear Unclear High High Low Unclear Low 
Giusti 2016 Low Low Low Low Low Low Low 
Gotfried 2007 Unclear Unclear High High Low Low Low 
Jiang 2017 Low Unclear High High Low Unclear Low 
Li 2010 Low Unclear High High High Unclear Low 
Llor 2009 Unclear Low Low Low Low Unclear Low 
Llor 2012 Low Unclear Low Low Low Low Low 
Nouira 2010 Low Low Low Low Low Low Low 
Park 2017 Unclear Low Low Low Low Unclear High 
Petitpretz 2007 Unclear Unclear High High High Unclear Unclear 
Prins 2019 Low Low High High Low Low Low 
Rhee 2015 Low Low Low Low High High High 
Ritchie 2019 Low Low Low Low Low Low Low 
Roede 2007 Low Low Low Low Low Unclear High 
Rohde 2015 Unclear Unclear Low Low     
Stallberg 2009 Unclear Low Low Low Low Low Low 
Stolz 2007 Unclear Unclear High High Low Low Low 
Urueta-Robledo 2006 Unclear Unclear Low Low High Unclear Unclear 
van den Broek 2008 Low Low Low Low Low Unclear Unclear 
van Zanten 2007 Unclear Unclear High High Low Unclear Low 
Verduri 2015 Low Low High High Low Low Low 
Wang 2010 Unclear Low Low Low Low High Unclear 
Xie 2019 Low Low High Low     
Yoon 2013 Low Low High High Low Unclear Unclear 
Zervos 2007 Unclear Unclear High High Low Unclear High 
Zhang 2019 Low Low Low Low       
Table 5. Definitions of various COPD exacerbation states within descriptive instruments. 
COPD Exacerbation States Described N 
Cure or Resolution  
 Complete resolution of all signs and symptoms of the exacerbation. 8 
 Sufficient improvement of the signs and symptoms such that no additional 
systemic treatments were prescribed. 
5 
 Anthonisen Respiratory Symptoms Score <5 [46]. 2 
 Three consecutive days when patients’ symptoms were back at their  
baseline, or seven consecutive days in which the patient only reported a  
“minor increase” in symptoms compared to baseline, without fever or change 
in sputum colour. 
2 
 Resolution of symptoms, signs, and laboratory findings. 1 
 Resolution of symptoms, signs, laboratory findings, and eradication of the 
causative organism. 
1 
 Remission (not further described). 4 
  
Marked Improvement  
 Resolution of all signs and symptoms of the exacerbation, or reduction of 
at least 3 points in a non-validated score, compared to baseline. 2 
 Only one of the following parameters remains abnormal: clinical  
symptoms, signs, laboratory findings, causative pathogen (not eradicated). 
1 
 Major symptoms including cough, exacerbation, and dyspnoea almost  
disappeared and the chest imaging was significantly improved. 
1 
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 Significantly improved symptoms, signs, and laboratory tests. 
Effectiveness index between 60–90% (based on a non-validated scale). 1 
  
Improvement  
 Improved signs and symptoms, without any new signs or symptoms. 4 
 Improved symptoms as evaluated by clinical scores: Anthonisen  
Respiratory Symptoms Score between 6–10; 30% improvement in the  
Bronchitis Severity Score (BSS); reduction of 1–3 points in a non-validated 
score. 
3 
 Improved, but more than one of the following parameters remain  
abnormal: clinical symptoms, signs, laboratory findings, causative pathogen 
(not eradicated). 
1 
 Improved symptoms, signs, and laboratory tests. Effectiveness index  
between 30–60% (based on a non-validated scale). 1 
 Resolution of at least 50% of symptoms back to the baseline level. 1 
 Resolution of fever with incomplete resolution of signs and symptoms, 
without the need for additional antibiotics. 
1 
 Resolution or reduction of the symptoms and signs without new 
symptoms and signs associated with the infection. 1 
 Improvement (not further described). 4 
  
Treatment Failure  
 Lack of resolution of signs and symptoms, requiring additional treatment, 
(or death). 
8 
 Persistence or worsening of signs and symptoms, or death. 7 
 Lack of resolution of signs and symptoms or need for further treatment. 4 
 Persistence or worsening of signs, symptoms, or laboratory tests. 1 
 Worsening of at least one symptom, or no change in the symptoms, or  
reduction of less than 3 points in a non-validated score, compared to baseline. 1 
 Ineffective treatment (not further described). 3 
The proportion of participants experiencing treatment failure based on these 
outcomes increased over time, as all participants fulfilling the criteria of treatment failure 
at any time until the selected timepoint were considered to have experienced the outcome 
(treatment failure). Importantly, treatment failure assessed at a later follow-up usually 
also included patients experiencing a re-exacerbation. As anticipated, treatment failure 
rates and slopes over time were higher among people admitted to the hospital or treated 
in the intensive care unit (ICU). When assessed between one and two weeks from 
recruitment, the median (range) of the treatment failure rates across the included studies 
were 8.3% (6–10.6%) in the emergency setting, 6.5% (1.5–13.5%) in the hospital setting, 
and 19.3% (15.3–34.2%) in the ICU setting. At three months follow-up, in studies 
conducted in the hospital setting, over half of the participants were identified as having 
experienced treatment failure. Moreover, 40% of participants treated in the community 
and 30% of those assessed in the emergency department were also anticipated to have 
experienced treatment failure at three months. 
The proportions of study participants fulfilling descriptive criteria for (a) cure, (b) 
marked improvement, (c) improvement, or (d) treatment failure, at different timepoints, 
are summarised in Figure 2. These states were evaluated at different timepoints, up to one 
month from recruitment, except for two studies that assessed cure or treatment failure at 
three months (not depicted in Figure 2). 
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Figure 2. (a) Cure, (b) marked improvement, (c) improvement, or (d) treatment failure assessed using descriptive 
measurement instruments among participants in arms of the included trials that received treatments/interventions that 
are consistent with current clinical practice guidelines (i.e., study arms with experimental interventions that are not 
consistent with current clinical practice were excluded from this analysis). 
When assessed between one and two weeks from recruitment, the median (range) of 
cure rates across the included studies were 74.5% (0–96.5%) in the community setting, 
30.6% (30.5–30.7%) in the emergency setting, 36.4% (12.5–67.2%) in the hospital setting, 
and 30.2% (18.6–41.9%) in the NIV setting. The median (range) for marked improvement 
were 85.0% (28.9–96.9%) in the hospital and 45.1% (34.1–56.1%) in the NIV setting. The 
respective figures for improvement were 85.1% (64.9–92.8%) in the community, 81% (80.6–
81.5%) in the emergency, 84.6% (68.6–100%) in the hospital, and 79.1% (65.9–90.2%) in the 
NIV settings. Finally, treatment failure rates were 10.0% (1.8–22.0%) in the community, 
8.0% (7.7–8.3%) in the emergency, 15.4% (0–24.4%) in the hospital, and 20.9% (9.8- 34.1%) 
in the NIV settings. 
Overall, the proportion of participants experiencing cure or marked improvement 
varied significantly during the first two weeks of follow-up, largely due to the significant 
variability in the outcome definitions. Stricter instruments, such as those requiring a 
complete resolution of all signs and symptoms associated with the exacerbation to confirm 
cure yielded lower cure rates, while higher rates were observed with more lenient 
definitions. Most of the included studies assessed patients treated in the community, or in 
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the hospital for their exacerbation. As anticipated, cure rates were generally higher among 
participants treated in the community compared to those hospitalised, for any given 
follow-up timepoint. 
The proportion of participants experiencing improvement or treatment failure varied 
less across the included studies and was less dependent on the instruments or timepoints 
of evaluation. 
3.4. Measurement Timepoints and Treatment Effects 
Finally, we explored treatment effects observed on the overall outcome of the 
exacerbations in superiority trials comparing an intervention hypothesised to be superior 
to the control group treatment by the trial investigators. Our aim was to explore whether 
specific instruments or measurement timepoints are more likely to yield a positive result. 
Forest plots summarising the findings from eligible outcomes are presented in Figures 3 
and 4. 
Composite treatment failure outcomes appear to infrequently yield significant results 
(3/11, 27% of the evaluated outcomes; it should be noted that two of the three outcomes 
revealing a positive effect among hospitalised patients represent different timepoints from 
the same trial). We did not observe an association between specific measurement 
instruments or timepoints and positive treatment effects. 
 
Figure 3. Treatment effects on treatment failure rates in superiority trials assessing treatment failure as a composite 
outcome. The left-hand side favours the intervention. N: study population. 
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Figure 4. Treatment effects on treatment failure rates in superiority trials assessing cure, marked improvement, 
improvement, or treatment failure defined using descriptive instruments. The left-hand side favours the intervention. N: 
study population. 
Over half of the outcomes evaluating cure or improvement yielded significant 
results, while 40% of those assessing treatment failure using descriptive instruments also 
yielded significant results. Nonetheless, the main difference between outcomes yielding 
positive or negative results was the study population of the included studies, rather than 
the measurement instruments or timepoints. Only two studies included in this analysis 
evaluated marked improvement, and the lack of any positive treatment effects most likely 
reflects the limited study population included in the respective analyses. 
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4. Discussion 
This methodological systematic review evaluated the instruments used to assess 
treatment success or failure in RCTs of COPD exacerbations management and the 
timepoints in which these outcomes are measured. We found substantial heterogeneity in 
both the instruments and timepoints, which could significantly hinder the interpretability 
and comparability of the trial results. We identified two broad groups of measurement 
instruments assessing treatment success or failure: (i) composite outcomes consisting of 
several undesirable outcomes of exacerbations, together defining an overall unfavourable 
outcome; and (ii) instruments defining treatment success or failure based on qualitative 
or semi-quantitative descriptions of the patients’ clinical status with regards to their 
exacerbation. We present the rate of participants anticipated to experience treatment 
success or failure at different timepoints after recruitment in different trial settings, and 
these figures could be used to inform power calculations for future trials. Available data 
from eligible studies did not suffice to identify an optimal instrument or timepoint for 
evaluating treatment success or failure in COPD exacerbations. 
Composite treatment failure measurement instruments are characterised by a critical 
drawback. They group together components that bear a very different impact (utility) on 
patients, such as death versus the need for supplement oxygen [71]. Importantly, the 
relative frequency of these outcomes may vary across the different exacerbation subtypes, 
thus limiting the interpretability of the results. For example, exacerbations caused by a 
bacterial infection are associated with higher mortality, while an increased re-
hospitalisation rate is observed in exacerbations characterised by enhanced eosinophilic 
inflammation [2,72]. Moreover, our analysis suggests that composite instruments are less 
sensitive in identifying treatment effects compared to descriptive instruments, as fewer 
studies using composite instruments identified a statistically significant effect in trials 
evaluating interventions that the investigators hypothesised were superior to the control 
treatments. While this finding is indirect and based on a small number of observations, it 
may reflect a limited sensitivity of these instruments. Finally, the ERS COPD 
exacerbations core outcome set recommends that most of the components of these 
composite outcomes should be assessed as independent outcomes, thus providing 
additional granularity in the trial results, while in parallel limiting the utility of composite 
instruments assessing treatment success or failure [12]. 
More trials used descriptive instruments for assessing the overall outcome of 
exacerbations. These instruments are limited by the subjectivity of assessing the severity 
of the clinical conditions by patients and clinicians alike. As a result, these instruments 
may be susceptible to performance and detection bias. A similar limitation is accepted in 
the methodology used to classify exacerbations by severity, depending on the clinician’s 
judgement around the need for systemic treatments or hospital admission [8,73]. These 
problems spring from the significant heterogeneity that characterises acute exacerbations 
of COPD and from the lack of clinically validated clinical biomarkers or objective indices, 
that could facilitate severity assessment or confirmation of cure. 
In the absence of adequate data to select an optimal measurement instrument for 
assessing the cure of an exacerbation, the ERS COPD exacerbations core outcome set panel 
recommended an interim instrument for evaluating this outcome based on the evidence-
informed consensus among the panel members and participating patient representatives. 
It is recommended that treatment success (cure) should be defined as the sufficient 
improvement of the signs and symptoms of the exacerbation such that no additional 
systemic treatments (systemic corticosteroids or antibiotics) are required [12]. This 
instrument aligns with the definitions of COPD exacerbations severity and is a practical 
outcome that is routinely considered in daily clinical practice and often used in trials. In 
parallel, the panel issued a recommendation for methodological research to develop 
objective and accurate methods for confirming the cure of COPD exacerbations. 
The most frequently used descriptive instrument defined cure as complete resolution 
of all signs and symptoms of an exacerbation. However, this instrument was not adopted 
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in the core outcome set due to limitations that may have limited its usability. Firstly, large 
observational studies have demonstrated that the recovery period of an exacerbation 
varies and may be very prolonged [74,75]. It has been suggested that one in four patients 
experience persistent symptoms compared to their pre-exacerbation status in excess of 25–
35 days after the exacerbation’s onset [74,75], while recovery of the patient’s pre-
exacerbation exercise capacity or activities of daily living may be further delayed [76,77]. 
Moreover, acute exacerbations expedite the progression of COPD. As a result, the clinical 
condition of patients after recovery from an exacerbation may be characterised by a 
greater symptomatic burden compared to the previous baseline [77]. Therefore, 
anticipating the complete resolution of all signs and symptoms caused by the exacerbation 
may not be appropriate; in addition, this outcome may be more susceptible to subjectivity 
in the assessment of the potentially limited and clinically insignificant remaining 
symptoms during recovery. 
Another interesting instrument defined treatment success as the first of three days 
while patients’ symptoms are back at their baseline, or the first of seven days in which 
patients only report a minor increase in symptoms compared to baseline, without fever or 
change in sputum colour. This instrument has only been used in a limited number of trials 
and is not adequately validated, and for this reason it was not adopted by the core 
outcome set panel. However, this outcome may provide more consistency and allow 
trialists to measure more accurately time-to-treatment success. Therefore, it may be worth 
being further validated in future trials. 
There is significant variability in the terms used to describe treatment success, such 
as cure, resolution, or remission. Cure may be a confusing term, since COPD is a chronic, 
incurable disease. On the other hand, remission is associated with negative connotations 
(cancer). Treatment success or resolution are more appropriate terms. 
Treatment success or failure is frequently evaluated as an outcome in other acute 
respiratory diseases as well, including community, hospital-acquired, or ventilator-
associated pneumonia, COVID-19, and acute asthma [78,79] [unpublished data]. Trialists 
face similar challenges in the selection of appropriate instruments for evaluating this 
outcome in these acute respiratory diseases [78] [unpublished data]. We were not able to 
identify any other methodological studies evaluating instruments for measuring 
treatment success or failure in any acute respiratory diseases. 
As previously mentioned, the course and outcomes, but also treatment responses of 
different COPD exacerbation subtypes, such as those caused by bacterial or viral 
infections, or those characterised by enhanced eosinophilic inflammation, vary 
significantly [2,72,80,81]. Clinical trialists should consider conducting more personalised 
trials, focusing on specific exacerbation subtypes, as the study populations, treatment 
effects, and outcomes would be more homogeneous and more easily interpretable. 
Current data strongly suggest that the therapeutics of COPD exacerbations will progress 
through precision medicine approaches [2,82]. 
This meta-epidemiological study was limited by the inadequate number of included 
RCTs and was therefore not able to identify an optimal instrument and timepoints for 
assessing treatment success in clinical trials in COPD exacerbations. We only included 
trials published from 2006 onwards. However, we considered that the inclusion of older 
trials might have introduced heterogeneity in our findings, as the diagnosis, severity 
stratification, and management of exacerbations may have differed in studies conducted 
previously. Similarly, clinical trial methodology has changed over the last decades and so 
has our approach towards trial outcomes. Moreover, we did not include data from 
observational studies, as our work focuses on clinical trials and the instruments used in 
observational studies are often different. 
The thorough systematic search, which included the Cochrane Airways Trials 
Register, sourcing clinical trials from five electronic databases, and the abstract 
proceedings of all major international respiratory conferences, is one of the strengths of 
this study. Another major strength is the thorough analysis of the instruments used to 
Biomedicines 2021, 9, 1837 14 of 21 
 
assess treatment failure, the timepoints at which they were evaluated, and the results they 
yielded. Finally, the last part of this manuscript was informed by the consensus 
discussions of a multi-stakeholder panel with a global representation, described in the 
main task force report [12]. 
5. Conclusions 
Various instruments and timepoints are currently used to assess treatment failure in 
clinical trials evaluating COPD exacerbation management. Further methodological 
studies are needed to identify the optimal instrument. In the meantime, in line with the 
ERS COPD exacerbations core outcome set, we recommend that COPD trials should 
evaluate treatment success based on the need for additional systemic treatments after the 
completion of the initial treatment of the exacerbation. 
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Search strategy 
Chronic Obstructive Pulmonary Disease: 
#1 Chronic Obstructive Pulmonary Disease [MH] 
#2 Lung Diseases, Obstructive [MH:NOEXP] 
#3 Emphysema [MH]  
#4 Chronic Bronchitis [MH] 
#5 COPD [tiab] 
#6 COAD [tiab]  
#7 “Chronic Bronchitis” [tiab] 
#8 Emphysema [tiab] 
#9 Obstructive[ti]  
#10 (Pulmonary OR Respiratory OR Airway OR Airflow OR Lung)[ti] 
#11 #9 AND #10 
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #11 
 
Disease exacerbations: 
#13 Disease Exacerbation [MH] 
#14 Exacerbation [tiab] 
#15 Exacerbation* [tiab] 
#16 #13 OR #14 OR #15 
 
RCT filter: 
#17 randomized controlled trial [pt] 
#18 controlled clinical trial [pt] 
#19 randomized [tiab]  
#20 placebo [tiab] 
#21 clinical trials as topic [mesh: noexp] 
#22 randomly [tiab] 
#23 trial [ti] 




#26 Systematic[tiab] and (review[tiab]) 
#27 Meta analysis[publication type] 
#28 Meta-analysis[tiab] 
#29 Metaanalysis[tiab] 
#30 #25 OR #26 OR #27 OR #28 OR #29 
 
#31 Search (“2006”[Date-Publication]: “2020”[Date-Publication]) 
#32 animals [mh] NOT humans [mh] 
#33 #12 AND #16 AND #31 AND (#24 OR #30) 
#34 #33 NOT #32 
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